EX-99 4 lon353249.htm EXHIBIT 99.2 - FINANCIALS Exhibit
Exhibit 99.2

ASML - Summary Consolidated Statements of Operations (1)


Three months ended              
(Amounts in thousands except per share data) March 30,
2003
EUR
March 30,
2004
EUR

     
Net sales  318,042  453,485 
Cost of sales  265,169  307,516(2) 

Gross profit on sales  52,873  145,969 
     
Research and development costs  80,345  74,663 
Research and development credits  (4,480) (4,822)
Selling, general and administrative expenses  61,063  47,707 
Restructuring expenses  6,443  (5,862)

Total expenses  143,371  111,686 
     
Operating income (loss) from continuing 
operations  (90,498) 34,283 
Interest income (expense), net  (7,034) (4,058)

     
Income (Loss) from continuing operations before 
income taxes  (97,532) 30,225 
Benefits from (provision for) income taxes on 
income from continuing operations  28,843  (9,672)

     
Net income (loss) from continuing operations  (68,689) 20,553 
     
Loss from discontinued operations 
before income tax  (21,836)
Benefits from income taxes on discontinued 
operations  8,625 

Net loss from discontinued operations  (13,211)
     
Net income (loss)  (81,900) 20,553 
Basic net income (loss) per ordinary share:  (0.17) 0.04 
Diluted net income (loss) per ordinary share:  (0.17) 0.04 
     
     
Number of ordinary shares used in computing per share amounts (in thousands): 
Basic  482,182  482,867 
Diluted  482,182  485,383 

1.) Except for consolidated statements of operations for the year ended December 31, 2003 and balance sheet data as of December 31, 2003, all figures are unaudited.
2.) Includes positive adjustment of EUR 2.7 million for restructuring charges.




ASML - Ratios and Other Data(1)

Three months ended
March 30,
 
March 28,
 
 
2003


2004


Gross profit on sales from continuing operations          
                         as a % of net sales   16.6   32.2  
      Operating income (loss) from continuing  
               operations as a % of net sales   (28.5)   7.6  
 Net income (loss) from continuing operations  
                          as a % of net sales   (21.6)   4.5  
  Shareholders' equity as a % of total assets   38.0   39.1  
                 Sales of new systems (units)   27   42  
                Sales of used systems (units)   6   16  
               Sales of systems total (units)   33   58  
         Backlog Sales of new systems (units)   87   135  
        Backlog Sales of used systems (units)   6   28  
       Backlog Sales of systems total (units)   93   163  
 Number of employees in continuing operations   5,762   5,005  
Number of employees in discontinued operations   499   -  
                    Number of employees total   6,261   5,005  


ASML - Summary Consolidated Balance Sheets(1)

  March 30, June 30, Sept. 28, Dec. 31, March 28,
2003 2003 2003 2003 2004
(Amounts in thousands)
EUR
EUR
EUR
EUR
EUR
ASSETS           
Cash and cash equivalents  688,297  1,249,905  1,103,848  1,027,806  1,152,022 
Accounts receivable, net  434,898  323,444  301,129  314,495  317,368 
Inventories, net  778,547  733,738  675,582  595,017  599,110 
Other current assets  353,896  151,650  154,496  207,502  237,919 
Assets held for sale  93,057  77,065  76,699  5,007 

Total current assets  2,348,695  2,535,802  2,311,754  2,149,827  2,306,419 
           
Deferred tax asset  343,975  360,188  378,636  325,271  335,262 
Other assets  60,316  67,445  71,294  30,711  32,274 
Intangible assets  13,510  12,940  15,503  14,590  13,660 
Property, plant and equipment  475,531  437,120  392,907  347,883  326,135 

Total assets  3,242,027  3,413,495  3,170,094  2,868,282  3,013,750 
 
LIABILITIES AND SHAREHOLDERS' EQUITY 
Current liabilities  749,409  650,767  559,397  673,068  776,389 
Liabilities held for sale  54,296  49,518  58,460  13,451 
Convertible subordinated bonds  1,038,476  1,354,464  1,224,018  842,543  862,292 
Long term debt and deferred liabilities  166,832  184,497  184,729  198,013  196,280 
Shareholders' equity  1,233,014  1,174,249  1,143,490  1,141,207  1,178,789 

Total liabilities and Shareholders' equity  3,242,027  3,413,495  3,170,094  2,868,282  3,013,750 



ASML - Summary Consolidated Statements of Cash Flows(1)

  Three months ended          
March 30, March 28,
2003 2004
(Amounts in thousands)
EUR
EUR
     
CASH FLOWS FROM OPERATING ACTIVITIES:     
Net income (loss) from continuing operations  (68,689) 20,553 
Depreciation and amortization  35,283  25,734 
Change in tax assets and tax liabilities  (38,995) 4,619 
Change in assets and liabilities  131,239  57,964 

Net cash provided by operating 
activities from continuing operations  58,838  108,870 
 
CASH FLOWS FROM INVESTING ACTIVITIES: 
Capital expenditures  (25,428) (12,010)
Other investing activities  6,560  14,448 

Net cash provided by (used in) investing activities 
from continuing operations  (18,868) 2,438 

Net cash provided by operating and 
investing activities from continuing operations  39,970  111,308 
 
CASH FLOWS FROM FINANCING ACTIVITIES: 
Redemption and/or repayment of loans  (384) (304)
Proceeds from share issuance  7,678 

Net cash provided by (used in) financing 
activities from continuing operations  (384) 7,374 

Net cash flow from continuing operations  39,586  118,682 
Effect of changes in exchange rates on cash  (8,081) 5,534 
Net cash flow provided by (used in) 
discontinued operations  (11,968)

Net increase in cash and cash equivalents  19,537  124,216 



ASML - Quarterly Summary Consolidated Statements of operations (1)


Three months ended,
(Amounts in millions) March 30,
2003
EUR
June 30,
2003
EUR
Sept. 28,
2003
EUR
Dec. 31,
2003
EUR
March 28,
2004
EUR

ASSETS          
Net Sales 318.0 329.1 370.0 525.5 453.5
Cost of Sales 265.2 256.6 276.6 375.5 307.5

Gross profit on sales 52.8 72.5 93.4 150.0 146.0

Research and development costs, net of credits 75.9 73.0 61.8 76.1 69.8
 Selling, general and administrative expenses 61.0 54.9 50.3 46.3 47.7
Restructuring expenses 6.4 18.0 (5.8)

Total expenses 143.3 145.9 112.1 122.4 111.7
Operating income (loss) from continuing
operations (90.5) (73.4) (18.7) 27.6 34.3
Interest income (expense), net (7.0) (9.4) (8.4) (4.3) (4.1)

Income (loss) from continuing operations before
Income taxes (97.5) (82.8) (27.1) 23.3 30.2
Provision for income taxes on income from
continuing operations 28.8 28.9 9.5 (7.6) (9.7)

Net income (loss) from continuing operations (68.7) (53.9) (17.6) 15.7 20.5
           
Net loss from discontinued operations (13.2) (9.6) (12.9)
Net income (loss) (81.9) (63.5) (30.5) 15.7 20.5



ASML - Quarterly Summary Ratios and other data(1)

    Three months ended,      
  March 30, June 30, Sept. 28, Dec. 31, March 28,
2003 2003 2003 2003 2004

Gross profit on sales of continuing operations as                      
a % of net sales    
16.6 
 
22.0 
  25.2   
28.5 
  32.2 
Operating income (loss) from continuing  
operations as a % of net sales    
(28.5) 
 
(22.3) 
  (5.1)   
5.3 
 
7.6 
Net income (loss) from continuing operations as  
a % of net sales    
(21.6) 
 
(16.4) 
  (4.7)   
3.0 
 
4.5 
Shareholders' equity as a % of total assets    
38.0 
 
34.4 
   36.1  
39.8 
 
39.1 
Sales of new systems (units)    
27 
 
28 
  28   
43 
 
42 
Sales of used systems (units)      
13 
   
18 
 
16 
Sales of systems total (units)     33    41    34   
61 
 
58 
Backlog Sales of new systems (units)     87    56    80   
103 
 
135 
Backlog of Sales used systems (units)         11   
21 
 
28 
Backlog Sales of systems total (units)     93    62    91   
124 
 
163 
Value of backlog new systems (EUR million)     870    653    817   
946 
 
1,293 
Value of backlog used systems (EUR million)     19    25    42   
47 
 
64 
Value of backlog systems total (EUR million)     889    678    859   
993 
 
1,357 
Number of employees in continuing operations     5,762    5,529    5,218   
5,059 
  5,005 
Number of employees in discontinuing operations     499    524    408   
119 
 
Number of employees total     6,261    6,053    5,626   
5,178 
  5,005 



ASML — Notes to the Summary Consolidated Financial Statements

Basis of Presentation

ASML follows accounting principles generally accepted in the United States of America (“U.S. GAAP”). Further disclosures, as required under U.S. GAAP in annual reports, are not included in the summary consolidated financial statements. The accompanying consolidated financial statements are stated in thousands of euros (‘EUR’).

Principles of consolidation

The consolidated financial statements include the accounts of ASML Holding N.V. and all of its majority-owned subsidiaries. All inter-company profits, transactions and balances have been eliminated in the consolidation.

Recognition of revenues, income and expenses

ASML distinguishes between revenues from “new” and “proven” technology systems. Revenue for “proven technology” systems is recognized upon shipment, since title passes to the customer at that moment, and the customer has unconditionally accepted the system during a factory test prior to shipment. Revenues on “new technology” systems are deferred until installation and acceptance at the customer’s premises are completed. As soon as a track record has been established regarding the successful and timely installation and acceptance of equipment previously identified as “new technology,” ASML considers the equipment to be “proven technology”. At that time, ASML changes the timing of revenue recognition to the shipment date in accordance with its revenue policy for “proven technology” and recognizes previously deferred revenue.

The fair value of installation services provided to customers is initially deferred and is recognized when installation is completed. Sales from service contracts are recognized when performed. Revenue from prepaid service contracts is recognized over the life of the contract.

Use of estimates

The preparation of ASML’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities on the balance sheet dates and the reported amounts of revenue and expense during the reported periods. Actual results could differ from those estimates.

‘Safe Harbor’ Statement under the U.S. Private Securities Litigation Reform Act of 1995: the matters discussed in this document include forward-looking statements that are subject to risks and uncertainties including, but not limited to, economic conditions, product demand and industry capacity, competitive products and pricing, manufacturing efficiencies, new product development, ability to enforce patents, the outcome of intellectual property litigation, availability of raw materials and critical manufacturing equipment, trade environment, and other risks indicated in filings with the U.S. Securities and Exchange Commission.